Format

Send to

Choose Destination
Trends Immunol. 2012 Nov;33(11):571-7. doi: 10.1016/j.it.2012.07.003. Epub 2012 Aug 8.

Interleukin-6: from an inflammatory marker to a target for inflammatory diseases.

Author information

1
Department of Medicine/Immunobiology, University of Vermont, Burlington, VT 05405, USA. mrincon@uvm.edu

Abstract

The incidence and diversity of chronic inflammatory diseases is increasing worldwide. However, the complexity of clinical symptoms has made it difficult to develop therapies that provide a substantial improvement for extended periods of time in a wide range of patient groups. Thus, there is a need for new therapies that target inflammatory responses without compromising immune defense. Interleukin (IL)-6, one of the first identified cytokines, has recently been recognized as a potential target in inflammatory disease. Here, I discuss how this cytokine has evolved from being a marker of inflammation to a successful target to control inflammation. I will summarize the results from the recent clinical studies using IL-6 receptor blockade, and describe potential mechanisms by which IL-6 can contribute to the progression of inflammatory diseases.

PMID:
22883707
DOI:
10.1016/j.it.2012.07.003
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center